Roche Holding AG (RHHBF)
OTCMKTS · Delayed Price · Currency is USD
337.60
0.00 (0.00%)
Jul 18, 2025, 4:00 PM EDT
Roche Holding AG Revenue
In the year 2024, Roche Holding AG had annual revenue of 62.40B CHF with 3.23% growth. Roche Holding AG had revenue of 31.64B in the half year ending December 31, 2024, a decrease of -0.86%.
Revenue
62.40B CHF
Revenue Growth
+3.23%
P/S Ratio
3.76
Revenue / Employee
604.32K CHF
Employees
103,249
Market Cap
259.19B USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 84.04M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.70M |
Roche Holding AG News
- 12 hours ago - Genentech Provides Update on Supplemental Biologics License Application for Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma - Business Wire
- 10 days ago - Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others - CNBC
- 18 days ago - Lomiko Metals Announces Ruisseau Graphite Project Exploration Update, La Roche Zone Extension and Fall Workplan - Business Wire
- 18 days ago - Changes to the Roche Enlarged Corporate Executive Committee - GlobeNewsWire
- 25 days ago - Roche Holding AG (RHHBY) Virtual Hematology Investor Conference Transcript - Seeking Alpha
- 25 days ago - Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars - Benzinga
- 4 weeks ago - Roche's Genentech reports positive results from lymphoma trial - Seeking Alpha
- 4 weeks ago - Roche's Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma - GlobeNewsWire